ES3052989T3 - Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 - Google Patents

Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Info

Publication number
ES3052989T3
ES3052989T3 ES21162316T ES21162316T ES3052989T3 ES 3052989 T3 ES3052989 T3 ES 3052989T3 ES 21162316 T ES21162316 T ES 21162316T ES 21162316 T ES21162316 T ES 21162316T ES 3052989 T3 ES3052989 T3 ES 3052989T3
Authority
ES
Spain
Prior art keywords
antagonist
seq
variant
eosinophilic
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21162316T
Other languages
English (en)
Spanish (es)
Inventor
Shannon Bruse
Shane Mccarthy
Aris Baras
Frederick Dewey
Omri Gottesman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3052989T3 publication Critical patent/ES3052989T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES21162316T 2017-04-13 2018-03-20 Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 Active ES3052989T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762485077P 2017-04-13 2017-04-13

Publications (1)

Publication Number Publication Date
ES3052989T3 true ES3052989T3 (en) 2026-01-16

Family

ID=61911717

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21162316T Active ES3052989T3 (en) 2017-04-13 2018-03-20 Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Country Status (12)

Country Link
US (2) US11708415B2 (cg-RX-API-DMAC7.html)
EP (3) EP3957752B1 (cg-RX-API-DMAC7.html)
JP (3) JP7321939B2 (cg-RX-API-DMAC7.html)
KR (2) KR102751957B1 (cg-RX-API-DMAC7.html)
CN (2) CN110431240B (cg-RX-API-DMAC7.html)
AU (3) AU2018252974B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059350A1 (cg-RX-API-DMAC7.html)
ES (1) ES3052989T3 (cg-RX-API-DMAC7.html)
IL (3) IL314591B1 (cg-RX-API-DMAC7.html)
MX (2) MX2019012171A (cg-RX-API-DMAC7.html)
SG (1) SG11201909457XA (cg-RX-API-DMAC7.html)
WO (1) WO2018190990A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP7165618B2 (ja) * 2019-04-23 2022-11-04 ジェネシスヘルスケア株式会社 アレルギー性鼻炎のリスクを判定する方法
MX2021013427A (es) * 2019-05-01 2022-01-31 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
EP4430211A1 (en) * 2021-11-11 2024-09-18 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN101426518A (zh) * 2006-01-11 2009-05-06 艾罗文斯公司 用于治疗人类和非-人类灵长类中哮喘的方法和组合物
FR2900817B1 (fr) * 2006-05-12 2008-12-19 Gambro Lundia Ab Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient
CN1896275B (zh) * 2006-06-29 2010-04-07 四川大学华西医院 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2010067381A1 (en) * 2008-12-12 2010-06-17 Decode Genetics Ehf Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
ES2549637T3 (es) 2011-02-23 2015-10-30 F. Hoffmann-La Roche Ag Anticuerpos contra IL33R humano y la utilización de los mismos
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
US10703799B2 (en) * 2012-12-10 2020-07-07 Vib Vzw IL-33R and IL-1RAcP fusion proteins
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−33拮抗薬とその使用法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) * 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック, インコーポレイテッド 抗インターロイキン−33抗体及びその使用
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CN104531689A (zh) * 2014-12-12 2015-04-22 上海交通大学医学院附属新华医院 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
JP6858182B2 (ja) * 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.

Also Published As

Publication number Publication date
KR20230164197A (ko) 2023-12-01
KR102751957B1 (ko) 2025-01-09
RU2019136253A (ru) 2021-05-13
US20230374145A1 (en) 2023-11-23
RU2019136253A3 (cg-RX-API-DMAC7.html) 2021-12-17
AU2018252974B2 (en) 2024-10-17
US12612462B2 (en) 2026-04-28
AU2024220214A1 (en) 2024-11-07
US11708415B2 (en) 2023-07-25
IL269873A (en) 2019-11-28
JP2024163308A (ja) 2024-11-21
EP3957752B1 (en) 2025-08-20
CN121951033A (zh) 2026-05-01
MX2024002689A (es) 2024-03-20
SG11201909457XA (en) 2019-11-28
CN110431240B (zh) 2026-02-24
KR20190140928A (ko) 2019-12-20
IL327281A (en) 2026-05-01
EP3957752A2 (en) 2022-02-23
AU2024220214B2 (en) 2026-07-23
JP2020516289A (ja) 2020-06-11
CA3059350A1 (en) 2018-10-18
US20200031922A1 (en) 2020-01-30
EP4549586A2 (en) 2025-05-07
AU2024220212B2 (en) 2026-08-13
JP7321939B2 (ja) 2023-08-07
IL314591B1 (en) 2026-05-01
AU2024220212A1 (en) 2024-11-07
WO2018190990A1 (en) 2018-10-18
KR102605045B1 (ko) 2023-11-27
EP4549586A3 (en) 2025-07-23
JP2023129607A (ja) 2023-09-14
MX2019012171A (es) 2019-11-25
CN110431240A (zh) 2019-11-08
EP3610041A1 (en) 2020-02-19
EP3957752A3 (en) 2022-06-15
AU2018252974A1 (en) 2019-11-28
IL314591A (en) 2024-09-01
IL269873B2 (en) 2025-01-01
IL269873B1 (en) 2024-09-01
JP7557581B2 (ja) 2024-09-27

Similar Documents

Publication Publication Date Title
JP7557581B2 (ja) Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
Atreya et al. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF?
Li et al. Eosinophilic gastroenteritis: pathogenesis, diagnosis, and treatment
Lee et al. The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy
JP5650871B1 (ja) そう痒を伴う疾患に罹患した患者のil−31アンタゴニストによる治療に対する応答を予測する方法
Galeone et al. Precision medicine in targeted therapies for severe asthma: is there any place for “omics” technology?
KR20230023663A (ko) Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP2018506528A (ja) Ibdにおける治療標的及びバイオマーカー
US20220290246A1 (en) Single nucleotide polymorphisms and uses thereof
JP2026514637A (ja) Il-17依存性病態のバイオマーカーに基づく治療および診断方法
HK40069286B (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
Lyu et al. Prediction and verification of potential therapeutic targets for non-responders to infliximab in ulcerative colitis
HK40069286A (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
Bank A Cohort of Anti-TNF Treated Danish Patients with Inflammatory Bowel Disease, Used for Identifying Genetic Markers Associated with Treatment Response: PhD Dissertation
RU2776241C2 (ru) Лечение и ингибирование воспалительных заболеваний легких у пациентов с аллелями риска в генах, кодирующих il33 и il1rl1
AU2020288361C1 (en) Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract
Stern The causes and treatment of kidney disease in scleroderma
Lee et al. Changes in Gene Expression in Fatty Acid Metabolism and De Novo Lipogenesis Are Conserved in Human CKD and Animal Models: SA-OR96
Lin Insights into Eosinophilic Esophagitis Using Computational Genomics and Bioinformatics